Group 1 - Jiangsu Securities Regulatory Bureau has enhanced its regular visiting mechanism for listed companies, achieving a coverage rate of 64.78% by visiting 458 companies as of July 31, 2023, and resolving 446 issues to promote better development [1] - The bureau focuses on key industries, such as automotive and home appliances, to help companies leverage national policies for quality improvement and efficiency, with nearly 90% of related companies achieving profitability [2] - In the pharmaceutical sector, the bureau has guided innovative drug companies to utilize capital markets for upgrades, with one company successfully obtaining FDA approval for a new drug [2] Group 2 - The bureau supports listed companies in financing and mergers, with equity financing reaching 51.233 billion yuan from January to July 2023, and 209 new merger and acquisition disclosures, totaling over 65.084 billion yuan [3] - A total of 83 listed companies in Jiangsu have announced buyback or increase plans, amounting to 15.924 billion yuan, while 160 companies plan to conduct mid-term dividends, a 11.72% increase year-on-year [4] - The bureau has established strategic cooperation agreements with 13 cities to enhance communication and support for listed companies, leading to the stable delisting of 6 ST companies this year [5]

Core Insights - Shanghai Lechun Biotechnology Co., Ltd. has disclosed its IPO counseling progress report (ninth phase) with China International Capital Corporation as the counseling institution [2] - Established in 2011, Lechun Biotechnology has a registered capital of 363 million yuan and operates in four main areas: single-use systems, filtration and purification, cell culture, and cleanroom contamination control [2] - The company has completed financing and acquisition plans for several entities, including Ge's Fluid, Kangsheng Biotechnology, Stanley Think, and Feiding, between 2023 and 2024 [2]